CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million
payment from GlaxoSmithKline (GSK) related to the advancement of its
program to develop antisense drugs to treat hepatitis B virus (HBV).
"Our collaboration with GSK has been very productive resulting in
three novel antisense drugs in our pipeline. We look forward to
continuing to advance these drugs and add additional new drugs to our
pipeline with GSK," said B. Lynne Parshall, chief operating officer at Isis. "Including the $1 million announced today, we have earned $11 million in payments from GSK to discover and develop drugs for HBV."
"HBV infection is a serious health problem that can lead to
significant and potentially fatal health conditions, including
cirrhosis, liver failure and liver cancer. While chronic HBV is
currently treated with oral antiviral agents or injectable interferons,
these treatments do not clear HBV and do not effectively clear HBV
antigens from these patients. This means that patients are unable to
fully control HBV infection and achieve sustained disease remission. As
such, more effective HBV agents that provide greater viral inhibition
and permit greater immune system activity against the virus are needed.
We believe that using our antisense approach we can develop a drug that
has the potential to fill this patient need," said C. Frank Bennett, Ph.D., senior vice president, research at Isis.
As part of Isis' strategic alliance with GSK, Isis is discovering and
developing drugs to treat HBV, which GSK has the exclusive option to
in-license and further develop and commercialize after Isis completes
the first clinical proof of concept study. Isis is eligible to earn
pre-licensing payments from GSK as the HBV program advances in
development. Isis is also eligible to receive double-digit royalties on
sales from any product that GSK successfully commercializes under this
strategic alliance with GSK, including those arising out of this HBV
program.
Read complete release here...
Labels: antisense, drugs in development, ISIS